Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Science. 2021 Jan 15;371(6526):300-305. doi: 10.1126/science.abd9836.
Signaling through the CD19-CD81 co-receptor complex, in combination with the B cell receptor, is a critical determinant of B cell development and activation. It is unknown how CD81 engages CD19 to enable co-receptor function. Here, we report a 3.8-angstrom structure of the CD19-CD81 complex bound to a therapeutic antigen-binding fragment, determined by cryo-electron microscopy (cryo-EM). The structure includes both the extracellular domains and the transmembrane helices of the complex, revealing a contact interface between the ectodomains that drives complex formation. Upon binding to CD19, CD81 opens its ectodomain to expose a hydrophobic CD19-binding surface and reorganizes its transmembrane helices to occlude a cholesterol binding pocket present in the apoprotein. Our data reveal the structural basis for CD19-CD81 complex assembly, providing a foundation for rational design of therapies for B cell dysfunction.
通过 CD19-CD81 共受体复合物与 B 细胞受体的信号转导是 B 细胞发育和激活的关键决定因素。目前尚不清楚 CD81 如何与 CD19 结合以发挥共受体功能。在这里,我们通过冷冻电镜(cryo-EM)报告了与治疗性抗原结合片段结合的 CD19-CD81 复合物的 3.8 埃结构。该结构包括复合物的细胞外结构域和跨膜螺旋,揭示了驱动复合物形成的胞外结构域之间的接触界面。与 CD19 结合后,CD81 打开其胞外结构域以暴露疏水性 CD19 结合表面,并重新组织其跨膜螺旋以封闭存在于无蛋白中的胆固醇结合口袋。我们的数据揭示了 CD19-CD81 复合物组装的结构基础,为 B 细胞功能障碍治疗的合理设计提供了基础。